ノグチ　レイ   NOGUCHI Rei   野口　玲    所属   医学部 医学科    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Gastric biopsy-derived cell line and its utility in assessing tumor cell drug sensitivity.
掲載誌名	正式名：Biomedical research (Tokyo, Japan) 略　 称：Biomed Res ISSNコード：1880313X/03886107
掲載区分	国外
巻・号・頁	46(1),pp.27-35
著者・共著者	Hayashi Masato, Noguchi Rei, Abe Makoto, Osaki Julia, Adachi Yuki, Iwata Shuhei, Sasaki Kazuki, Kondo Tadashi, Yoshimatsu Yuki*
担当区分	2nd著者
発行年月	2025
概要	Gastric cancer (GC) has benefited from treatment improvements such as minimally invasive surgery, molecular-targeted drugs, and immune check point inhibitors. However, the prognosis of advanced GC is still unfavorable. Minimally invasive pre-treatment detection of drug sensitivity (MI-PDDS) has increasing importance in view of improved chemotherapy. Gastric biopsy specimens are obtained with relative ease but have not been considered an appropriate source for generating cell lines because of their minute amounts. We therefore materialized the idea of MI-PDDS using biopsy-derived cell lines obtained from endoscopic biopsy specimens. Here, a cell line designated TCC-GC1-C1 was established from a biopsy specimen of a histologically confirmed adenocarcinoma of the stomach. The cell line showed the ability of forming spheroid with deeply stained nuclei and disturbed cellular morphology indicative of malignancy. Single-nucleotide polymorphism (SNP) genotyping of the cell line revealed a duplication of chromosome19q and a deletion of chromosome 8p. A drug screening test with 221 anticancer drugs showed that the cell line had high sensitivity to the proteasome inhibitor (Carfilzomib) and the fibroblast growth factor receptor inhibitor (Erdafitinib), with a low IC50 value of under 0.1 μM. Our MI-PDDS approach holds promise in making a treatment decision for advanced GC.
DOI	10.2220/biomedres.46.27
PMID	39894565